Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Medical Research Council/Uganda Virus Research Institute, Uganda Research Unit on AIDS, Entebbe, Uganda.
Lancet. 2009 Dec 19;374(9707):2080-2089. doi: 10.1016/S0140-6736(09)61674-3. Epub 2009 Nov 24.
Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care.
We undertook a cluster-randomised equivalence trial in Jinja, Uganda. 44 geographical areas in nine strata, defined according to ratio of urban and rural participants and distance from the clinic, were randomised to home-based or facility-based care by drawing sealed cards from a box. The trial was integrated into normal service delivery. All patients with WHO stage IV or late stage III disease or CD4-cell counts fewer than 200 cells per microL who started antiretroviral therapy between Feb 15, 2005, and Dec 19, 2006, were eligible, apart from those living on islands. Follow-up continued until Jan 31, 2009. The primary endpoint was virological failure, defined as RNA more than 500 copies per mL after 6 months of treatment. The margin of equivalence was 9% (equivalence limits 0.69-1.45). Analyses were by intention to treat and adjusted for baseline CD4-cell count and study stratum. This trial is registered at http://isrctn.org, number ISRCTN 17184129.
859 patients (22 clusters) were randomly assigned to home and 594 (22 clusters) to facility care. During the first year, 93 (11%) receiving home care and 66 (11%) receiving facility care died, 29 (3%) receiving home and 36 (6%) receiving facility care withdrew, and 8 (1%) receiving home and 9 (2%) receiving facility care were lost to follow-up. 117 of 729 (16%) in home care had virological failure versus 80 of 483 (17%) in facility care: rates per 100 person-years were 8.19 (95% CI 6.84-9.82) for home and 8.67 (6.96-10.79) for facility care (rate ratio [RR] 1.04, 0.78-1.40; equivalence shown). Two patients from each group were immediately lost to follow-up. Mortality rates were similar between groups (0.95 [0.71-1.28]). 97 of 857 (11%) patients in home and 75 of 592 (13%) in facility care were admitted at least once (0.91, 0.64-1.28).
This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care.
在非洲,寻找增加获得抗逆转录病毒疗法的新途径是当务之急。我们评估了家庭为基础的艾滋病护理与机构为基础的护理是否同样有效。
我们在乌干达的金贾开展了一项基于群组的等效性试验。根据城乡参与者的比例和离诊所的距离,将 44 个地理区域分为 9 个层,通过从盒子中抽取密封卡片将这些区域随机分配到家庭为基础或机构为基础的护理。该试验整合到了正常的服务提供中。所有在 2005 年 2 月 15 日至 2006 年 12 月 19 日期间开始接受抗逆转录病毒治疗的患有世卫组织第四期或晚期第三期疾病或 CD4 细胞计数少于每微升 200 个细胞的患者都符合条件,除了居住在岛屿上的患者。随访持续到 2009 年 1 月 31 日。主要终点是病毒学失败,定义为治疗 6 个月后 RNA 超过 500 拷贝/ml。等效性范围为 9%(等效性限值 0.69-1.45)。分析是根据意向治疗进行的,并根据基线 CD4 细胞计数和研究层进行了调整。这项试验在 http://isrctn.org 注册,编号为 ISRCTN 17184129。
859 名患者(22 个群组)被随机分配到家庭护理组,594 名患者(22 个群组)被分配到机构护理组。在第一年,93 名接受家庭护理的患者(11%)和 66 名接受机构护理的患者(11%)死亡,29 名接受家庭护理的患者(3%)和 36 名接受机构护理的患者(6%)退出,8 名接受家庭护理的患者(1%)和 9 名接受机构护理的患者(2%)失访。在家庭护理组中,729 名患者中有 117 名(16%)发生病毒学失败,而在机构护理组中,483 名患者中有 80 名(17%)发生病毒学失败:每 100 人年的发生率分别为家庭护理组 8.19(95%CI 6.84-9.82)和机构护理组 8.67(6.96-10.79)(比值比[RR] 1.04,0.78-1.40;等效性显示)。两组各有两名患者立即失访。两组的死亡率相似(0.95 [0.71-1.28])。在家庭护理组中,有 97 名患者(11%)至少入院一次,而在机构护理组中,有 75 名患者(13%)至少入院一次(0.91,0.64-1.28)。
这种以家庭为基础的艾滋病护理策略与以诊所为基础的策略同样有效,因此可以改善和公平地获得艾滋病毒治疗,特别是在基础设施薄弱和获得诊所护理困难的地区。